News

10.03.2021

CELLVIE CEO Dr. Alexander Schueller placed amongst the Top-17 contenders for the De Vigier Awards 2021

cellvie AG is proud to announce that CEO Dr. Alexander Schueller placed amongst the Top-17 contenders for the prestigious De Vigier Entrepreneurship Award.

The W.A. de Vigier Foundation promotes and supports innovative entrepreneurial spirit in Switzerland. Since 1987, the goal of the foundation has been to actively invigorate business development, providing financial support to young entrepreneurs, who stand out in the country’s innovation-rich business environment. Today, the De Vigier Award is one of the most respected prizes for young entrepreneurs in Switzerland, being awarded for especially high degrees of innovation, value creation for society as a whole, and the technical and financial viability of the founders’ company.

Every year, entrepreneurs can submit an application for the chance to pitch their idea, project, or company to a jury, in the hopes of reaching the final round with the possibility of winning CHF 100,000. Due to Covid-19 regulations, this year’s first De Vigier Award selection round was held digitally. Out of >200 applications 60 entrepreneurs were selected to present to the De Vigier Foundation jury on February 4, 2021.

cellvie is proud to announce that Alex Schueller, the company’s CEO and co-founder, was not only one of these 60 bright minds, invited to showcase their innovations, but prevailed amid fierce competition. He was selected to present cellvie’s innovative mitochondria therapy as one of the Top-17 young entrepreneurs in Switzerland, competing for the De Vigier Award’s grand prize.

Alex founded cellvie together with Drs. James McCully, Pedro del Nido and Sitaram Emani. Born in Germany, he studied business at the Maastricht University in The Netherlands, before joining The Boston Consulting Group. In the subsequent pursuit of his PhD, he came across a unique surgical glue technology, upon which he co-founded Adhesys Medical. This first venture of his was acquired by the Grunenthal Group in 2017.  With cellvie, Alex is particularly excited about the chance to contribute to what may emerge as a new treatment modality: the therapeutic use of mitochondria.

 

Alex’s presentation for the Top-60 competition of the De Vigier Awards can be watched here: https://www.youtube.com/watch?v=5782bnvEh9c

 

About cellvie AG

Founded in the US and headquartered close to Zürich in Switzerland, cellvie is developing medicines from cells, leveraging the therapeutic potential of mitochondria. The company was founded by Drs. McCully, Schueller, del Nido and Emani in 2018. Dr. McCully pioneered the approach of mitochondria augmentation and replacement at Harvard Medical School and the team has now set out to bring it about as a new treatment modality in ischemia-reperfusion injury, aging, and beyond. Since its founding cellvie has successfully expanded its team and operations close to Zürich.

Further information can be found at www.cellvie.bio.

Back to news
Line art Mitochondrium